Ligandal develops effective antidote to SARS-CoV-2

Ligandal, one of the world’s most innovative genetic medicine companies, today announces the positive results of laboratory studies that demonstrate the effectiveness of its synthetic peptide, SARS-BLOCK™, as a combination treatment and vaccine to COVID-19. 

The experiments, in conjunction with the Stroud Lab, University of California San Francisco, demonstrate SARS-BLOCK™halts infection of SARS-CoV-2. In addition to being an effective inhibitor of infection, SARS-BLOCK™ has high affinity with neutralising antibodies, enabling it to enhance the immune response to the SARS-CoV-2 virus. The results mean SARS-BLOCK™ shows real promise as a combination treatment and vaccine.

Andre Watson, CEO and Founder of Ligandal, says, “Our results so far have been very positive. We’ve demonstrated SARS-BLOCK™ inhibits ACE2 cellular entry of the SARS-CoV-2 spike protein. We have also established that SARS-BLOCK™ prevents infection of ACE2-expressing cells by the virus. We’re grateful for the work Professor Stroud and his team have done in helping us understand the efficacy of SARS-BLOCK™.”

The experiments demonstrate that Ligandal’s novel genetic medicine approach has yielded a very promising therapy to COVID-19. Ligandal modelled its approach by addressing the specific microbiological characteristics of the virus, rather than repurposing existing technology. As such, the firm has met the threat of SARS-CoV-2 with a completely new, specifically tailored response that allowed it to develop a combination treatment and vaccine. 

Adam Hamdy, a medical industry consultant and author, who recently joined the company’s advisory board says, “This is groundbreaking science. In 2007, Nobel Prize Winner Professor Rolf Zinkernagel hypothesised synthetic peptides could be used to inhibit viral infection and elicit an immune response. 13 years later, Ligandal’s synthetic peptide, SARS-BLOCK™, appears to have done exactly that.”

Andre Watson says, “The next step is for us to test SARS-BLOCK™ in animals and humans. If trials of SARS-BLOCK™prove successful, we expect to move to mass market manufacturing within 18 months. Our innovative, distributed manufacturing process means we will be able to respond to global demand very quickly.”

Adam Hamdy says, “SARS-BLOCK™ has significant advantages over other vaccines and therapies in development. It was designed to neutralise SARS-CoV-2 at a genetic level, and the results suggest it is effective at doing so. SARS-BLOCK™ is 100% room temperature stable and therefore can be easily deployed globally to any setting. We’re feeling very positive about both the cost and availability of the treatment.”